Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
IRVINE, Calif., Oct. 24, 2016 -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its third quarter 2016 financial results, which will take place on Tuesday, November 1, 2016 after the close of the market, and its 2016 Investor Meeting, which will take place November 17, 2016 at the Sheraton New York Times Square Hotel in New York City.
Third Quarter 2016 Conference Call Information
Endologix will hold a conference call on Tuesday, November 1, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the financial results of the third quarter 2016. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.endologix.com.
After the live webcast, a replay of the webcast will remain available online from the investor relations page of Endologix's website, www.endologix.com, through November 1, 2017. In addition, a transcript will be posted to website and a telephonic replay of the call will be available until November 8, 2016. The replay dial-in numbers are (844) 512-2921 for domestic callers and (412) 317-6671 for international callers. Please use the replay pin number 13648565.
2016 Investor Meeting
Endologix will hold its 2016 Investor Meeting on November 17, 2016 from 4:30 to 7:00 pm ET at the Sheraton New York Times Square Hotel in New York City. The event will include a Company update along with presentations from prominent physicians on the Company’s product portfolio and a question and answer session with the physicians and Endologix management.
| Event: | Endologix Investor Meeting | |
| Date: | November 17, 2016 | |
| Time: | 4:30 to 7:00 pm ET (registration and refreshments begin at 4:30 pm ET; formal presentation begins at 5:00 pm ET) | |
| Location: | Sheraton New York Times Square Hotel | |
| 811 7th Ave 53rd Street, New York, NY | ||
A live audio webcast of the investor meeting will be available by visiting the investor relations section of Endologix's website at www.endologix.com. Participants are encouraged to log on a few minutes prior to 5:00 pm ET in order to download any applicable audio software. A replay of the presentation will be available within 24 hours and will be available for approximately one year.
Please RSVP by contacting Brandon Vazquez at The Ruth Group at: [email protected] or 646-536-7032 by November 14, 2016.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
ENDOLOGIX CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020
